Recent Updates
Recently added Catalysts
SRXH Positive Sentiment Score: 75/100

SRx Health Solutions and EMJX Invest in Recent IPO and Commercial-Stage Pharmaceutical Company of Psychedelics, Optimi Health Corp. (OPTH)

Key Takeaway: SRx Health Solutions and EMJX have invested in Optimi Health Corp., a commercial-stage pharmaceutical company focused on psychedelic drug products. This investment is driven by strong insider ownership and favorable industry trends, particularly after a recent executive order aimed at accelerating psychedelic drug development. The companies are preparing for a proposed transaction, with relevant documents filed with the SEC.

Market Sentiment Analysis

POSITIVE FACTORS

  • Investment in Optimi Health Corp. indicates confidence in the psychedelic industry.
  • Strong corporate governance led by a reputable chairman.
  • Positive macro trends in the psychedelic sector following government support.

Full Press Release Details

NORTH PALM BEACH, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") and EMJ Crypto Technologies ("EMJX"), a digital-asset treasury operating platform with which the Company has entered into a definitive merger agreement, today announced investing in Optimi Health Corp. (NASDAQ: OPTH), a commercial-stage pharmaceutical company focused on manufacturing and distribution of GMP-grade psychedelic drug products for mental health therapies including Psilocybin.
The EMJX proprietary operating system applying quantitative models, artificial intelligence and systematic risk controls has identified Optimi Health Corp. as an investment opportunity for several reasons including high insider ownership of approximately 30% and strong corporate governance led by Chairman of the Board whose family founded Lululemon, John James (JJ) Wilson.
Additionally, the psychedelic industry is experiencing tailwinds after U.S. President Trump signed an executive order in April 2026 to accelerate psychedelic drug development and improve timelines and coordination with the FDA and DEA.
“Our proprietary AI technology investment platform can guide and identify investment themes,” said Michael Young, SRx Board Member. “This gives us a unique opportunity to invest in companies with positive macro and industry trends. Optimi has approximately 5.6 million shares outstanding, institutional ownership, as well as strong participation by management insiders on the IPO.”
Additional Information and Where to Find ItIn connection with the proposed transaction between the Company has filed with the SEC a Registration Statement on Form S-4 (the "Registration Statement") to register the common stock to be issued in connection with the proposed transaction. The Registration Statement includes an information statement of the Company and a prospectus of the Company (the "Information Statement/Prospectus"), and each of EMJX and the Company may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Information Statement/Prospectus will be sent to the stockholders This is not a substitute for the Registration Statement, the Information Statement/Prospectus or any other relevant documents that EMJX or the Company has filed or will file with the SEC. BEFORE MAKING ANY INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND INFORMATION STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT EMJX, THE COMPANY, THE PROPOSED TRANSACTION, AND RELATED MATTERS. A copy of the Registration Statement, Information Statement/Prospectus, as well as other relevant documents filed by EMJX and the Company with the SEC, may be obtained free of charge, when they become available, at the SEC's website at www.sec.gov. The information on EMJX's or the Company's respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.
No Offer or SolicitationThis communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "expect," "intend," "aim," "plan," "may," "could," "target," and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to, the ability to complete the proposed transaction, shareholder approvals, market conditions, regulatory considerations, and other risks described in the Company's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law.

Company ContactSRx Health Solutions, Inc.Kent Cunningham, Chief Executive Officer

Investor Relations ContactKCSA Strategic CommunicationsValter Pinto, Managing Director212-896-1254valter@kcsa.com

Frequently Asked Questions

What companies are involved in the investment?

The investment involves SRx Health Solutions and EMJ Crypto Technologies.

What is Optimi Health Corp. focused on?

Optimi Health Corp. focuses on manufacturing GMP-grade psychedelic drug products.

What recent government action supports the psychedelic industry?

An executive order signed by President Trump aims to accelerate psychedelic drug development.

What is the insider ownership percentage at Optimi Health?

Optimi Health has approximately 30% insider ownership.

Last updated: May 21, 2026